Serum soluble glycoprotein 130 concentration is inversely related to insulin sensitivity in women with polycystic ovary syndrome

Diabetes

Volumn 59, Issue 4, 2010, Pages 1026-1029

  Nikolajuk, Agnieszka ^a   Kowalska, Irina ^a   Karczewska Kupczewska, Monika ^a   Adamska, Agnieszka ^a   Otziomek, Elzbieta ^a   Wolczynski, Slawomir ^a   Kinalska, Ida ^a   Gorska, Maria ^a   Straczkowski, Marek ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; GLYCOPROTEIN; INSULIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; SEX HORMONE; SOLUBLE GLYCOPROTEIN 130; SOLUBLE INTERLEUKIN 6 RECEPTOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY FAT; BODY MASS; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; ANDROGENS; BODY MASS INDEX; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; GLYCOPROTEINS; HUMANS; INSULIN; KINETICS; LUTEINIZING HORMONE; OBESITY; POLYCYSTIC OVARY SYNDROME; REFERENCE VALUES; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; YOUNG ADULT;

EID: 77951158277     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db09-1316     Document Type: Article

References (25)

1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006-4011
2. Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000;85:2434-2438
3. Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 1999;84:1897-1899
4. Febbraio MA. gp130 receptor ligands as potential therapeutic targets for obesity. J Clin Invest 2007;117:841-849
5. Hirano T, Matsuda T, Nakajima K. Signal transduction through gp130 that is shared among the receptors for the interleukin 6 related cytokine subfamily. Stem Cells 1994;12:262-277
6. Taga T, Kishimoto T. gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 1997;15:797-819
7. Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002;51:3391-3399
8. Carey AL, Febbraio MA. Interleukin-6 and insulin sensitivity: friend or foe? Diabetologia 2004;47:1135-1142
9. Al-Khalili L, Bouzakri K, Glund S, Lönnqvist F, Koistinen HA, Krook A. Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. Mol Endocrinol 2006;20:3364-3375
10. Watt MJ, Dzamko N, Thomas WG, Rose-John S, Ernst M, Carling D, Kemp BE, Febbraio MA, Steinberg GR. CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK. Nat Med 2006;12:541-548
11. Narazaki M, Yasukawa K, Saito T, Ohsugi Y, Fukui H, Koishihara Y, Yancopoulos GD, Taga T, Kishimoto T. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 1993;82:1120-1126
12. Peters M, Jacobs S, Ehlers M, Vollmer P, Müllberg J, Wolf E, Brem G, Meyer zum Büschenfelde KH, Rose-John S. The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med 1996;183:1399-1406
13. Jones SA, Richards PJ, Scheller J, Rose-John S. IL-6 transsignaling: the in vivo consequences. J Interferon Cytokine Res 2005;25:241-253
14. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leuk Biol 2006;80:227-236
15. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long term health risk related to polycystic ovary syndrome (PCOS). Hum Rep 2004;19:41-47
16. Kowalska I, Straczkowski M, Nikolajuk A, Adamska A, Karczewska-Kupczewska M, Otziomek E, Wolczynski S, Gorska M. Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Hum Rep 2007;22:1824-1829
17. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-3672
18. Escobar-Morreale HF, Calvo RM, Villuendas G, Sancho J, San Millan JL. Association of polymorphisms in the interleukin 6 receptor complex with obesity and hyperandrogenism. Obesity Res 2003;11:987-996
19. Walch K, Grimm C, Zeillinger R, Huber JC, Nagele F, Hefler LA. A common interleukin-6 gene promoter polymorphism influences the clinical characteristics of women with polycystic ovary syndrome. Fertil Steril 2004;81: 1638-1641
20. Gottardo L, De Cosmo S, Zhang YY, Powers C, Prudente S, Marescotti MC, Trischitta V, Avogaro A, Doria A. A polymorphism at the IL6ST (gp130) locus is associated with traits of the metabolic syndrome. Obesity 2008; 16:205-210
21. Kawasaki F, Kawano Y, Kosay Hasan Z, Narahara H, Miyakawa I. The critical role of interleukin-6 and interleukin-6 soluble receptor in human follicular fluids. Clin Exp Med 2003;3:27-31
22. González F, Rote NS, Minium J, Kirwan JP. Evidence of proatherogenic inflammation in polycystic ovary syndrome. Metabolism 2009;58:954-962
23. Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Sancho J, San Millán JL. Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women. Diabetologia 2003;46:625-633
24. Möhlig M, Spranger J, Osterhoff M, Ristow M, Pfeiffer AF, Schill T, Schlösser HW, Brabant G, Schöfl C. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 2004;150:525-532
25. Esteve E, Villuendas G, Mallolas J, Vendrell J, Lopez-Bermejo A, Rodriguez M, Recasens M, Ricart W, San Millan JL, Escobar-Morreale HF, Richart C, Fernandez-Real JM. Polymorphisms in interleukin-6 receptor gene are associated with body mass index and with characteristics of the metabolic syndrome. Clin Endocrinol 2006;65:88-91